NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ...
I'm bullish on Harrow due to the VEVYE Access for All program, which makes dry eye treatment affordable and drives strong prescription growth. VEVYE's discounted pricing addresses a massive, ...
Throughout the last three months, 4 analysts have evaluated Harrow (NASDAQ:HROW), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results